Group 1 - The core viewpoint is that the innovative drug valuation recovery trend is ongoing, driven by multiple catalysts such as international conferences, tariff exemptions, BD transactions, and better-than-expected semi-annual performance [1] - The Hang Seng Pharmaceutical ETF (159892) has seen a continuous rise for six months, with a remarkable increase of 23.8% in July, ranking high among all market ETFs [1] - On August 1, the Hong Kong pharmaceutical sector continued to rise against the trend, with the Hang Seng Pharmaceutical ETF (159892) surging over 2%, led by companies like Lepu Biopharma, Ascentage Pharma, CSPC Pharmaceutical Group, and CanSino Biologics [1] Group 2 - CSPC Pharmaceutical Group recently announced a significant BD order, which includes a prepayment of $120 million, potential development, regulatory, and commercial milestone payments up to $1.955 billion, and high double-digit sales royalties based on the annual net sales of SYH2086 [1]
石药集团拿下超20亿美元BD大单！恒生医药ETF（159892）月K线6连阳，年内涨近90%